Cancer-Related Cognitive Impairment in Patients With a History of Breast Cancer | Breast Cancer | JAMA | JAMA Network
[Skip to Navigation]
Sign In
Views 10,876
Citations 0
JAMA Insights
Women's Health
October 15, 2021

Cancer-Related Cognitive Impairment in Patients With a History of Breast Cancer

Author Affiliations
  • 1Jonsson Comprehensive Cancer Center, Semel Institute, Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles,
  • 2Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, Fielding School of Public Health, University of California, Los Angeles
JAMA. 2021;326(17):1736-1737. doi:10.1001/jama.2021.13309

Clinical reports of cognitive difficulties in patients with breast cancer began to appear in the literature in the 1990s, coincident with the increasing use of postoperative adjuvant chemotherapy.1 Symptoms were more frequently reported in women who received very high-dose chemotherapy, raising concerns that cognitive impairment might become a dose-limiting treatment toxicity. However, this has not occurred, in that over the past 2 decades there has been a deescalation of both the intensity and generalized use of adjuvant chemotherapy in patients with breast cancer. Because of the initial association of cognitive symptoms with chemotherapy treatment, early research focused on what was referred to as chemobrain or chemofog, finding preliminary evidence of measurable neurocognitive effects among patients with breast cancer who were exposed to chemotherapy. Subsequent studies have documented cognitive changes before any cancer-directed therapies, as well as in association with other common breast cancer treatments (eg, radiation, endocrine therapy).

The evolving body of research on this subject led to a renaming of the condition as cancer-related cognitive impairment (CRCI). Although they are most commonly reported in close proximity to initial breast cancer treatments, for some patients, symptoms of CRCI can persist for years after treatment completion.2 Importantly, although breast cancer has been the most studied tumor type with CRCI, there is a growing literature on this condition in persons with other types of cancer, including lymphoma, head and neck cancers, and brain tumors, and patients who have received stem cell transplants.

Incidence and Nature of the Problem

CRCI reported by patients with breast cancer is common, although the frequency and nature can vary subject to the population sampled. According to one survey, 885 of 1147 patients (77%) with a history of breast cancer who received chemotherapy with and without endocrine therapy and 371 of 822 (45%) who received only endocrine therapy reported cognitive symptoms during or soon after treatment.3 A community-based prospective longitudinal cohort study of 503 patients with breast cancer, compared with 334 control participants without cancer, found statistically significant differences after adjuvant treatment in both self-reported clinically meaningful cognitive decline (36.5% vs 13.6% of participants)4 and neurocognitive decline (effect size 0.2 on the primary outcome as assessed by Janelsins et al).5 A meta-analysis of neuropsychological outcomes in patients with breast cancer treated with chemotherapy (n = 2939), compared with healthy control participants (n = 3420), revealed the largest effect sizes in the domains of processing speed and language (Cohen d = −0.39), executive function (Cohen d = −0.34), and memory (Cohen d = −0.30), but no differences compared with patients with breast cancer who were not treated with chemotherapy (n = 1538).6

In the current era of more selective chemotherapy use, cognitive symptoms continue to emerge in other contexts, including before any cancer-directed treatments, in association with endocrine therapy, and with radiotherapy and surgery.7 Patients who develop cognitive difficulties during the acute phase of breast cancer treatment may require several months to a year for recovery and, for some individuals, cognition never fully returns to “baseline,” supported by reports of neuroimaging abnormalities.7 Although cognitive symptoms rarely reach the level of severe impairment (ie, dementia), symptoms frequently disrupt functioning, work, and quality of life.7

Contributing Factors and Mechanisms

Several candidate mechanisms for CRCI have been hypothesized based on clinical and preclinical studies. Increased systemic inflammation occurs in response to cancer, as well as to chemotherapy, radiotherapy, and surgery.7 Chronically elevated inflammation can lead to neuroinflammation that could result in neurotoxicity and increased oxidative damage. Evidence has also implicated mitochondrial dysfunction in neurons as well as disrupted neurogenesis and neuroplasticity.7 The potential cognitive effects of immunotherapy, an emerging breast cancer therapy, will be important to monitor in light of patient reports and earlier studies.7

Endocrine therapy is used in the majority of patients with breast cancer and is another important potential risk factor for CRCI.8 Estrogen has an important role in women’s brain health, and the downregulation of natural estrogen production or blocking of its activity through endocrine therapy is associated with effects on cognition. Although research is still evolving in this area, a 2020 report from a randomized clinical trial involving 552 patients reported clinically meaningful patient-reported cognitive decline 12 months after starting endocrine therapy, with (37.7%) or without (35.3%) chemotherapy, and these difficulties were present in both premenopausal and postmenopausal women.9

Patient and context-related vulnerabilities for CRCI may include aging and preexisting medical conditions with known cognitive risk (eg, diabetes, heart disease). Genetic risk for CRCI is an ongoing area of study, with some evidence suggesting particular vulnerability among APOE*E4 carriers, the best-known genetic risk for Alzheimer disease. Preexisting and concurrent psychosocial risks for CRCI include mood symptoms (eg, depression) and trauma symptoms, fatigue, and sleep disturbance. In terms of protective factors, higher cognitive reserve may buffer against the neurotoxicity associated with cancer and its treatment.7

The leading model of CRCI suggests the possibility that it represents accelerated aging, given the overlap in mechanisms and vulnerabilities with cognitive aging. Some neuroimaging studies have described brain changes comparable to aging, such as compensatory hyperactivation during cognitive tasks and reduction in gray matter, as well as a link between markers of biological aging and cognition in patients with a history of cancer.7

Assessment and Treatment of CRCI

The National Comprehensive Cancer Network guidelines for the assessment and management of CRCI suggest that increased patient education regarding CRCI is important. Many patients with breast cancer are unaware of the possibility that they may have cognitive decline after treatment. Screening tools for dementia are insufficient for CRCI evaluation. Screening for mood disturbance and survivorship concerns can identify cognitive symptoms. Careful assessment of cognitive difficulties using validated questionnaires for CRCI can be used to track impairment if clinically suspected. When patients spontaneously report these symptoms to clinicians, they should not be ignored. Acknowledging the patient’s symptoms and undertaking a thorough evaluation is important. An initial first step should be examining and addressing potentially manageable associated conditions, such as depression, sleep disturbance, and fatigue, which are all common and frequently co-occurring in this patient population. If CRCI symptoms do not improve, a referral for neuropsychological evaluation should follow, because this can help characterize specific cognitive symptoms and supply targeted recommendations and may provide reassurance and information for patients who may be concerned that they are developing dementia.

There is no established standard care for neuroprotection against CRCI or for managing CRCI in the setting of breast cancer, and more evidence is needed. Cognitive rehabilitation and behavioral therapies are among the most promising interventions for CRCI to date.10 Physical exercise is a promising intervention but has not been adequately evaluated.7 Some pharmacologic agents have been studied (eg, psychostimulants, dementia medications) without conclusive efficacy, and more research is needed.

Summary

CRCI is an important clinical issue that can impair daily function, work productivity, childcare, and other responsibilities in patients with a history of breast cancer. Risk for CRCI includes cancer and cancer treatment, as well as patient-related vulnerabilities. Management recommendations include attending to patient-reported symptoms with a thorough symptom-targeted evaluation. Cognitive and behavioral treatments are the primary recommended intervention. More research is needed to establish a solid evidence base for CRCI that evolves alongside modern cancer treatment practices.

Submissions: The Women's Health editors welcome proposals for features in the section. Submit yours to ccrandall@mednet.ucla.edu.
Back to top
Article Information

Corresponding Author: Patricia A. Ganz, MD, UCLA Jonsson Comprehensive Cancer Center, 650 Charles Young Dr S, Room A2-125 CHS, Los Angeles, CA 90095-6900 (pganz@mednet.ucla.edu).

Published Online: October 15, 2021. doi:10.1001/jama.2021.13309

Conflict of Interest Disclosures: Dr Van Dyk reported receiving grants from the National Institutes of Health/National Cancer Institute outside the submitted work. Dr Ganz reported receiving grants from the Breast Cancer Research Foundation and grants from the National Cancer Institute and grants and personal fees from Blue Note Therapeutics outside the submitted work and being a member of a scientific advisory board of the Breast Cancer Research Foundation.

References
1.
Wefel  JS, Kesler  SR, Noll  KR, Schagen  SB.  Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults.   CA Cancer J Clin. 2015;65(2):123-138. doi:10.3322/caac.21258PubMedGoogle ScholarCrossref
2.
Hurria  A, Somlo  G, Ahles  T.  Renaming “chemobrain”.   Cancer Invest. 2007;25(6):373-377. doi:10.1080/07357900701506672PubMedGoogle ScholarCrossref
3.
Buchanan  ND, Dasari  S, Rodriguez  JL,  et al.  Post-treatment neurocognition and psychosocial care among breast cancer survivors.   Am J Prev Med. 2015;49(6)(suppl 5):S498-S508. doi:10.1016/j.amepre.2015.08.013PubMedGoogle ScholarCrossref
4.
Janelsins  MC, Heckler  CE, Peppone  LJ,  et al.  Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: an analysis from a nationwide, multicenter, prospective longitudinal study.   J Clin Oncol. 2017;35(5):506-514. doi:10.1200/JCO.2016.68.5826PubMedGoogle ScholarCrossref
5.
Janelsins  MC, Heckler  CE, Peppone  LJ,  et al.  Longitudinal trajectory and characterization of cancer-related cognitive impairment in a nationwide cohort study.   J Clin Oncol. 2018;36(32):JCO2018786624. doi:10.1200/JCO.2018.78.6624PubMedGoogle Scholar
6.
Bernstein  LJ, McCreath  GA, Komeylian  Z, Rich  JB.  Cognitive impairment in breast cancer survivors treated with chemotherapy depends on control group type and cognitive domains assessed: a multilevel meta-analysis.   Neurosci Biobehav Rev. 2017;83(May):417-428. doi:10.1016/j.neubiorev.2017.10.028PubMedGoogle Scholar
7.
Lange  M, Joly  F, Vardy  J,  et al.  Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors.   Ann Oncol. 2019:1-16. doi:10.1093/annonc/mdz410PubMedGoogle Scholar
8.
Ruddy  KJ, Ganz  PA.  Treatment of nonmetastatic breast cancer.   JAMA. 2019;321(17):1716-1717. doi:10.1001/jama.2019.3927PubMedGoogle ScholarCrossref
9.
Wagner  LI, Gray  RJ, Sparano  JA,  et al.  Patient-reported cognitive impairment among women with early breast cancer randomized to endocrine therapy alone versus chemotherapy followed by endocrine therapy: results from the trial assigning individualized options for treatment (TAILORx).   J Clin Oncol. 2020;38(17):1875-1886. doi:10.1200/JCO.19.01866PubMedGoogle ScholarCrossref
10.
Fernandes  HA, Richard  NM, Edelstein  K.  Cognitive rehabilitation for cancer-related cognitive dysfunction: a systematic review.   Support Care Cancer. 2019;27(9):3253-3279. doi:10.1007/s00520-019-04866-2PubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    1 Comment for this article
    EXPAND ALL
    Causes and Prevention
    Dilipsinh Solanki, MD | Private Practice
    We have been discussing “chemo-brain" for at least a decade.

    What is the cause, why just focus on breast cancer? There are others with other cancers who also need to function. Dr. Gans' focus on breast cancer is wonderful but this may not be just a breast cancer problem, and may not even have much to do with chemotherapy.

    Some years ago there were preclinical data showing a CNS protective effect of rEPO (1). Our group actually did a randomized study in women undergoing adjuvant chemotherapy; there was protection against short term memory impairment but no long
    term benefit.

    In the pages of JAMA Network, there was a study published from the Netherlands that reported a finding of neuronal autoantibodies in patients with NSCLC with correlation to cognitive deficits that were demonstrable before any treatment. They had found but not yet reported similar antibodies in patients with melanoma.

    How about undertaking a project like that?

    Even if what is suggested has benefit, I doubt that it can be adopted in a community practice which can barely do a geriatric assessment. Real world is tough all the way around!!

    References

    1. J Oncol Pharm Pract. 2005 Dec;11(4):145-9.doi: 10.1191/1078155205jp162oa 2. Bartels F, Wandrey M, Aigner A, et al. Association Between Neuronal Autoantibodies and Cognitive Impairment in Patients With Lung Cancer. JAMA Oncol. 2021;7(9):1302–1310. doi:10.1001/jamaoncol.2021.2049

    CONFLICT OF INTEREST: None Reported
    READ MORE
    ×